<DOC>
	<DOC>NCT01541189</DOC>
	<brief_summary>To evaluate efficacy and safety of valsartan 160mg in Chinese hypertensive patients.</brief_summary>
	<brief_title>Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Naive primary hypertension patients or primary hypertensive patients on mono antihypertensive therapy: All treatmentnaive patients need to have 140mmHg≤MSSBP&lt;180mmHg and 90mmHg≤MSDBP&lt; 110mmHg at visit 1 For patients on mono antihypertensive therapy, MSSBP/MSDBP should &lt;160/100mmHg at visit 1 (the beginning of screening period); and at visit 2(the beginning of theraputic period), they should have MSSBP≥140 mmHg and &lt;180mmHg AND MSDBP≥90 mmHg and &lt;110mmHg Severe hypertension Malignant hypertension Secondary hypertension Renal dysfunction(serum creatinine &gt; 2.0mg(176.8μmol/L)at visit 1) Hepatic disease History of hypertensive encephalopathy or cerebrovascular accident within 6 months History of myocardial infarction, coronary revascularization within 6 months Type 1 diabetes mellitus patietns with HbA1c &gt;8% at visit 1 Women in pregnancy and lactation Potentially fertile female patients not using effective contraceptive methods Be allergy to study drug. Other protocol defined inclusion/exlusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hypertension</keyword>
	<keyword>valsartan</keyword>
</DOC>